Trial Profile

Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-EGFR CAR-transduced T cells (Primary) ; Cyclophosphamide; Paclitaxel
Indications Cholangiocarcinoma; Colorectal cancer; Liver metastases; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions

Most Recent Events

14 Nov 2017 Results of phase I part of this study (n=19) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
28 Sep 2015 Planned number of patients changed from 10 to 60, according to ClinicalTrials.gov record.
28 Sep 2015 Results at the 5th World Congress on Cancer Therapy, according to a Cellular Biomedicine Group media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com